Nu 3

Drug Profile

Nu 3

Alternative Names: Bisphosphocin Nu-3; Nu-3; Nubiotics

Latest Information Update: 04 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Oligos Etc.
  • Developer Lakewood Amedex
  • Class Antibacterials
  • Mechanism of Action Cell membrane structure modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Diabetic foot ulcer
  • Preclinical Lung disorders
  • No development reported Burn infections; Lyme disease; Onychomycosis; Urinary tract infections

Most Recent Events

  • 27 Sep 2017 Efficacy data from a phase I/II trial in Diabetic foot ulcer released by Lakewood-Amedex
  • 27 Sep 2017 Lakewood-Amedex completes a phase I/II trial in Diabetic foot ulcer (In adults, In the elderly) in USA (Topical) (NCT02737722)
  • 22 Aug 2017 Lakewood Amedex completes enrolment in its phase IIa trial for Diabetic foot ulcer in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top